Treats anemia due to chronic kidney disease (CKD). Sold as Jesduvroq. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Daprodustat (sold as Jesduvroq), first approved Feb 1, 2023, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Jesduvroq | Part D | $0K | -100% | 0 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing DialysisChronic Kidney Disease (Stages 3b-5), Anemia Associated With Chronic Kidney Disease · Services Hospital, Lahore | Not applicable | Not yet recruiting | Aug 10, 2026 |
| REDCURE Registry for Chronic Kidney Disease (CKD) AnemiaCKD Anemia · Nabiqasim Industries (Pvt) Ltd | — | Not yet recruiting | Jan 16, 2026 |
| A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Anaemia · Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Dec 23, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 1, 2023 | JesduvroqNDA 216951 · New molecular entity | Glaxosmithkline | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Glaxosmithkline